Dec 23, 2019
Allergan Receives U.S. FDA Approval for UBRELVY(TM) for the Acute Treatment of Migraine with or without Aura in Adults
Dec 19, 2019
Amgen And Allergan Submit Biologics License Application For ABP 798, Biosimilar Candidate To Rituxan® (rituximab), To U.S. Food And Drug Administration
Dec 19, 2019
Allergan Foundation Giving Reaches $95 Million Since Inception
Dec 16, 2019
BOTOX® (onabotulinumtoxinA) Celebrates 30 Years of Endless Innovation
Dec 04, 2019
Allergan Announces Positive Phase 3 ACHIEVE I Trial Results for Ubrogepant Published in The New England Journal of Medicine
Nov 29, 2019
Announcement under the Irish Takeover Rules: Relevant Securities in Issue - November 29, 2019
Nov 05, 2019
Allergan Reports Third Quarter 2019 Financial Results
Oct 28, 2019
FDA Approves Medicines360's LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Six Years, the Longest Approved Duration of Use of Any Hormonal IUDs
Oct 25, 2019
AbbVie Announces Commencement of Exchange Offers and Consent Solicitations for Allergan Notes
Oct 25, 2019
Allergan Declares Fourth Quarter 2019 Cash Dividend of $0.74 Per Ordinary Share
Oct 23, 2019
Allergan Presents Data From Eleven Abstracts At The 2019 American Society for Dermatologic Surgery (ASDS) in Chicago
Oct 17, 2019
Allergan to Report Third Quarter 2019 Financial Results
Oct 14, 2019
Allergan Shareholders Approve Proposed Acquisition by AbbVie
Oct 11, 2019
Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration
Oct 10, 2019
On World Sight Day, Allergan Launches National Campaign to Raise Awareness of the Toll Glaucoma Takes on Everyday Living
Oct 07, 2019
The Aesthetic Society Develops 'The Patient App' Through Support From Allergan®
Oct 03, 2019
Allergan to Showcase Late-Stage Data in Age-Related Macular Degeneration and Glaucoma at American Academy of Ophthalmology Annual Meeting
Sep 27, 2019
Allergan and AbbVie Receive Second Request from Federal Trade Commission on Pending Transaction
Sep 27, 2019
AbbVie and Allergan Receive Second Request from Federal Trade Commission on Pending Transaction
Sep 20, 2019
AbbVie Inc. - Despatch of Option Holder Proposal Letters